CAR-T: THE FUTURE OF IMMUNOTHERAPY.

Introduction: Immunotherapy has transformed cancer treatment by leveraging historical observations of spontaneous tumor regression linked to infections. Pioneers like Fehleisen and Coley laid the groundwork for utilizing the immune system against cancer, contrasting with traditional treatments by targeting tumors with reduced side effects. Objective: This study aims to explore the efficacy of CAR-T cell therapy in cancer treatment and evaluate the role of biomedical professionals in its implementation and monitoring. CAR-T therapy involves genetically modifying a patient's T cells to enhance their ability to recognize and eliminate cancer cells, offering a promising avenue for advancing cancer treatment. Methods: The methodology involved a comprehensive review of current literature on CAR-T therapy, focusing on its structural components, mechanisms of action, clinical applications across various cancers (such as ALL, DLBCL, and MM), and associated challenges in safety and toxicity management. Results: CAR-T therapy has demonstrated significant efficacy in treating refractory leukemia and lymphomas, achieving complete remission in some cases. The therapy involves genetically modifying T cells to express chimeric antigen receptors (CARs) that target specific antigens on cancer cells. This activation triggers immune responses leading to tumor cell destruction, supported by the release of cytokines and induction of apoptosis. Despite notable successes, challenges such as cytokine release syndrome and the need for improved targeting strategies remain significant. Conclusion: CAR-T therapy represents a pivotal advancement in cancer treatment, offering personalized and effective options for patients previously resistant to conventional therapies. The ongoing evolution of CAR-T technology and collaborative efforts among researchers, healthcare providers, and regulatory bodies are crucial for enhancing its safety, efficacy, and accessibility worldwide.